Abstract
Stimulation of Group I metabotropic glutamate receptors (mGluR1 and mGluR5) leads to activation of a wide variety of signalling pathways. mGluRs couple to Gαq/11 proteins, activating phospholipase Cβ1 resulting in both diacylglycerol and inositol-1,4,5- triphosphate formation followed by the activation of protein kinase C. In addition, mGluR activation can lead to modulation of a number of ion channels, such as different types of calcium and potassium channels. Group I mGluRs can also activate other downstream protein kinases, such as ERK1/2 and AKT, which are implicated in cellular growth, differentiation, and survival. Moreover, Group I mGluRs interact with a variety of different proteins that are important for the regulation of synaptic signalling, such as Homer and PDZ domain containing proteins, such as Tamalin. A role for mGluR1/5 in a number of disease states has also been proposed. As mGluR1/5 signal transduction is complex and involves multiple partners, a better understanding of alterations in mGluR signalling in brain disorders will be required in order to discern the molecular and cellular basis of these pathologies. This review will highlight recent findings concerning mGluR signaling alterations in brain pathologies, such as stroke, fragile X syndrome, Alzheimers disease, Parkinsons disease, Huntingtons disease, epilepsy, and drug addiction.
Keywords: Metabotropic glutamate receptors, mGluR1/5, Gαq/11 proteins, stroke, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, drug addiction
CNS & Neurological Disorders - Drug Targets
Title: Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
Volume: 9 Issue: 5
Author(s): Fabiola M. Ribeiro, Maryse Paquet, Sean P. Cregan and Stephen S. G. Ferguson
Affiliation:
Keywords: Metabotropic glutamate receptors, mGluR1/5, Gαq/11 proteins, stroke, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, drug addiction
Abstract: Stimulation of Group I metabotropic glutamate receptors (mGluR1 and mGluR5) leads to activation of a wide variety of signalling pathways. mGluRs couple to Gαq/11 proteins, activating phospholipase Cβ1 resulting in both diacylglycerol and inositol-1,4,5- triphosphate formation followed by the activation of protein kinase C. In addition, mGluR activation can lead to modulation of a number of ion channels, such as different types of calcium and potassium channels. Group I mGluRs can also activate other downstream protein kinases, such as ERK1/2 and AKT, which are implicated in cellular growth, differentiation, and survival. Moreover, Group I mGluRs interact with a variety of different proteins that are important for the regulation of synaptic signalling, such as Homer and PDZ domain containing proteins, such as Tamalin. A role for mGluR1/5 in a number of disease states has also been proposed. As mGluR1/5 signal transduction is complex and involves multiple partners, a better understanding of alterations in mGluR signalling in brain disorders will be required in order to discern the molecular and cellular basis of these pathologies. This review will highlight recent findings concerning mGluR signaling alterations in brain pathologies, such as stroke, fragile X syndrome, Alzheimers disease, Parkinsons disease, Huntingtons disease, epilepsy, and drug addiction.
Export Options
About this article
Cite this article as:
M. Ribeiro Fabiola, Paquet Maryse, P. Cregan Sean and S. G. Ferguson Stephen, Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361612
DOI https://dx.doi.org/10.2174/187152710793361612 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Native Proteins in Organic Chemistry. Recent Achievements in the use of non Hydrolytic Enzymes for the Synthesis of Pharmaceuticals
Current Organic Chemistry Gene Therapy for Ischemic Brain Diseases
Current Gene Therapy Delirium Secondary to Lamotrigine Toxicity
Current Drug Safety Placental Drug Disposition and Its Clinical Implications
Current Drug Metabolism Epilepsy and Neurosurgery: Historical Highlights
Current Pharmaceutical Design Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry <i>In-Silico</i> Validation and Fabrication of Matrix Diffusion-Based Polymeric Transdermal Patches for Repurposing Gabapentin Hydrochloride in Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Crosstalk between Inflammation and the BBB in Stroke
Current Neuropharmacology The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Synthesis and DPPH Radical Scavenging Activity of 5-Arylidene-N,Ndimethylbarbiturates
Medicinal Chemistry How Early is Too Early? A Review of Infant Seizure Surgery Literature
Current Pediatric Reviews Meldrum's Acid in Organic Synthesis, an Outlook to Reaction Media
Current Organic Chemistry Zebrafish as an Animal Model to Study Epileptic Seizures and Epileptic Syndromes
Current Psychopharmacology Effects on the Post-translational Modification of H3K4Me3, H3K9ac, H3K9Me2, H3K27Me3, and H3K36Me2 Levels in Cerebral Cortex, Hypothalamus and Pons of Rats after a Systemic Administration of Cannabidiol: A Preliminary Study
Central Nervous System Agents in Medicinal Chemistry Early Detection of Epileptic Seizures in Sparse Domains
Neuroscience and Biomedical Engineering (Discontinued) 5-HT2C Receptor Agonists as Potential Drugs for the Treatment of Obesity
Current Topics in Medicinal Chemistry Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Targeting γ-Aminobutyric Acid (GABA) Carriers to the Brain: Potential Relevance as Antiepileptic Pro-Drugs
Medicinal Chemistry Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology